CORDIS
EU research results

CORDIS
English EN

IN-Silico trials for treatment of acute Ischemic STroke

Objective

Stroke is the number one cause of disability in the Western world and the 3rd most common cause of death. Despite new treatment options with intra-arterial thrombectomy, still 2 out of 3 patients still have a poor outcome. The main goal of INSIST is to advance treatments of ischemic stroke and its introduction in clinical practice by realizing in silico clinical stroke trials in which stroke and treatment are modeled. We will generate virtual populations of stroke patients, generate and validate in silico models for intra-arterial thrombectomy, thrombosis and thrombolysis, and microvascular perfusion and neurological deterioration after stroke, and integrate the in silico models to realize an in silico clinical stroke trial. We are uniquely positioned by the availability of a large pool of clinical, imaging, histopathological, and outcome data from multiple recently finalized stroke trials, a large registry (totaling 4500 patients), and new trials that will start later this year (totaling 2500 patients). We will build a population model that takes this input to generate virtual populations of stroke patients addressing the wide variety of patient characteristics. We will build on existing and emerging in silico models to validate reusable models for stroke and stroke treatment with a strong interaction with experimenting modeling in laboratories. The in silico models and virtual populations will be combined to simulate clinical trials and validated by simulating and comparing finalized and currently running trials. The in silico models will be used to simulate clinical trials to evaluate effectiveness and safety of novel devices and medication, both for the device as well as the pharmacological industry. For the device industry, we will evaluate the optimal configuration of thrombectomy stents for reduction of thrombus fragmentation. From the perspective of the pharmacy industry, we will simulate the effect of increased TAFIa on the effectiveness of alteplase.

Programme(s)

H2020-EU.3.1.5. - Methods and data

Topic(s)

SC1-PM-16-2017 - In-silico trials for developing and assessing biomedical products

Call for proposal

H2020-SC1-2017-CNECT-2

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Address

Meibergdreef 15
1105az Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 908 085

Website

Contact the organisation

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 545 750

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 717 500

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 568 125

NEURAVI LIMITED

Ireland

EU Contribution

€ 416 275

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland

EU Contribution

€ 425 365

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 462 500

POLITECNICO DI MILANO

Italy

EU Contribution

€ 349 600

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 771 975

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

France

EU Contribution

€ 85 500

M.V. LOMONOSOV MOSCOW STATE UNIVERSITY

Russia

Project information

Grant agreement ID: 777072

 Project website

Status

Ongoing project

  • Start date

    1 November 2017

  • End date

    31 October 2021

Funded under:

H2020-EU.3.1.5.

  • Overall budget:

    € 5 550 675

  • EU contribution

    € 5 250 675

Coordinated by:

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

Download

PDF XML

Last update: 29 July 2019

Record number: 212452